Regeneron Pharmaceuticals Inc. Common Stock (NASDAQ: REGN)
45 Days left to seek lead plaintiff status.
The complaint alleges Defendants provided investors with material information concerning Regeneron’s Phase III clinical trial of Fianlimab, a LAG-3 inhibitor, in combination with cemiplimab, a PD-1 inhibitor, as a first-line treatment for metastatic or locally advanced melanoma (the “Phase III Fianlimab-Libtayo Study”). Defendants’ statements included, among other things, overwhelming confidence in the drug combination’s potential for success and a mischaracterization of the additional structural risk imposed on the study by the prolonged slowdown in event accruals.